Clover Health posted Q4 2025 total revenues of USD 487.7 million (+44.7%) and a net loss from continuing operations of USD 49.3 million. Consolidated gross profit was USD 74.2 million (-21%), while adjusted EBITDA was a loss of USD 23.3 million (not compared due to a change from positive to negative). Total cash, cash equivalents, and investments ended Q4 at USD 319.9 million (-26.9%). For FY 2025, Clover Health reported total revenues of USD 1.9 billion (+40.3%), a GAAP net loss from continuing operations of USD 85.5 million (+84.7%), consolidated gross profit of USD 355.9 million (-2.4%), adjusted EBITDA of USD 21.7 million (-69%), and adjusted net income from continuing operations of USD 20.0 million (-70.7%). FY 2025 Medicare Advantage membership was 113,803 (+38%), and insurance revenue was USD 1.9 billion (+40.7%). The company said it generated FY 2025 adjusted EBITDA profitability while growing membership and insurance revenue, and highlighted 2026 AEP growth of 53% year-over-year with strong returning member retention. For FY 2026, Clover Health guided to total revenues of USD 2.81 billion to USD 2.92 billion, adjusted EBITDA of USD 50 million to USD 70 million, and GAAP net income of USD 0 million to USD 20 million, with average Medicare Advantage membership of 154,000 to 158,000. Management said it expects improving cohort economics driven by Clover Assistant to support its first full year of GAAP net income profitability in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Health Investments Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602261605PRIMZONEFULLFEED9662494) on February 26, 2026, and is solely responsible for the information contained therein.
Comments